{"id":70277,"date":"2026-07-20T14:13:14","date_gmt":"2026-07-20T06:13:14","guid":{"rendered":"https:\/\/flcube.com\/?p=70277"},"modified":"2026-07-20T14:13:14","modified_gmt":"2026-07-20T06:13:14","slug":"easton-pharmaceutical-secures-nmpa-approval-for-chinas-first-generic-remimazolam-besylate-challenging-humanwells-ruima-monopoly-in-procedural-sedation-and-general-anesthesia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70277","title":{"rendered":"Easton Pharmaceutical Secures NMPA Approval for China&#8217;s First Generic Remimazolam Besylate, Challenging Humanwell&#8217;s Ruima Monopoly in Procedural Sedation and General Anesthesia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Easton Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688513:SHA\">SHA: 688513<\/a>) announced that its <strong>generic version of remimazolam besylate<\/strong> has received <strong>approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for two key indications: <strong>(1) sedation and anesthesia in non-intubated surgical\/procedural settings<\/strong>; and <strong>(2) induction and maintenance of general anesthesia<\/strong>. This marks <strong>China&#8217;s first generic approval<\/strong> of remimazolam besylate, deemed <strong>therapeutically equivalent<\/strong> to the original under <strong>Generic Quality Consistency Evaluation (GQCE)<\/strong> requirements.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Approving Authority<\/strong><\/td><td>China National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Remimazolam besylate generic injection<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>1. Sedation\/anesthesia in non-intubated procedures<br>2. Induction\/maintenance of general anesthesia<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Easton Pharmaceutical Co., Ltd (SHA: 688513)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>20 Jul 2026<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>First generic version approved in China<\/td><\/tr><tr><td><strong>Bioequivalence<\/strong><\/td><td>Confirmed under GQCE requirements<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-context-amp-originator-background\" class=\"wp-block-heading\">Market Context &amp; Originator Background<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Original Developer:<\/strong> PAION AG (Germany)<\/li>\n\n\n\n<li><strong>China Rights Holder:<\/strong> Yichang Humanwell Pharmaceutical Co., Ltd.<\/li>\n\n\n\n<li><strong>Original Product Approval:<\/strong> July 2020 as <strong>Category 1 chemical drug<\/strong><\/li>\n\n\n\n<li><strong>Brand Name:<\/strong> <strong>Ruima<\/strong> (Yichang Humanwell)<\/li>\n\n\n\n<li><strong>Market Exclusivity Period:<\/strong> 6 years (expired July 2026)<\/li>\n\n\n\n<li><strong>Therapeutic Class:<\/strong> Ultra-short-acting benzodiazepine sedative\/anesthetic<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Player<\/th><th>Product<\/th><th>Status<\/th><th>Market Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Yichang Humanwell<\/strong><\/td><td>Ruima (remimazolam besylate)<\/td><td>Original Category 1 drug<\/td><td>Market leader since 2020; premium pricing<\/td><\/tr><tr><td><strong>Easton Pharmaceutical<\/strong><\/td><td>Generic remimazolam besylate<\/td><td>First generic approved<\/td><td>Price disruptor; immediate market share opportunity<\/td><\/tr><tr><td><strong>Other Domestic Manufacturers<\/strong><\/td><td>Various generics in development<\/td><td>Pipeline stage<\/td><td>Likely to follow within 12-24 months<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-amp-commercial-advantages\" class=\"wp-block-heading\">Clinical &amp; Commercial Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Benefits:<\/strong> Rapid onset, short duration, and favorable safety profile compared to traditional benzodiazepines<\/li>\n\n\n\n<li><strong>Procedural Applications:<\/strong> Ideal for colonoscopy, bronchoscopy, cardiac catheterization, and other short-duration procedures<\/li>\n\n\n\n<li><strong>Hospital Adoption Drivers:<\/strong><\/li>\n\n\n\n<li><strong>Cost savings:<\/strong> Generic pricing expected to be 40-60% below originator<\/li>\n\n\n\n<li><strong>Supply security:<\/strong> Multiple suppliers reduce single-source dependency risks<\/li>\n\n\n\n<li><strong>Reimbursement alignment:<\/strong> GQCE approval ensures inclusion in hospital formularies<\/li>\n\n\n\n<li><strong>Patient Benefits:<\/strong> Consistent quality with reduced treatment costs for self-pay procedures<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-assessment\" class=\"wp-block-heading\">Market Opportunity Assessment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Procedural Sedation Market:<\/strong> China performs an estimated 50+ million sedation-requiring procedures annually<\/li>\n\n\n\n<li><strong>Current Penetration:<\/strong> Remimazolam currently used in &lt;5% of eligible procedures due to premium pricing<\/li>\n\n\n\n<li><strong>Generic Impact:<\/strong> Price reduction expected to increase market penetration to 15-20% within 24 months<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Combined procedural sedation and general anesthesia market exceeds \u00a53 billion ($420 million) annually<\/li>\n\n\n\n<li><strong>Easton&#8217;s Advantage:<\/strong> First-mover generic status provides 6-12 month window before additional competitors enter<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Pressure:<\/strong> Humanwell likely to implement defensive pricing strategies to maintain market share<\/li>\n\n\n\n<li><strong>Hospital Procurement:<\/strong> Centralized procurement processes will accelerate generic adoption in public hospitals<\/li>\n\n\n\n<li><strong>Export Potential:<\/strong> Easton may leverage Chinese approval to pursue international generic registrations<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success demonstrates Easton&#8217;s capability in complex injectable generic development<\/li>\n\n\n\n<li><strong>Investor Impact:<\/strong> Positive catalyst for Easton&#8217;s valuation; potential margin expansion from high-value generic portfolio<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial prospects for generic remimazolam besylate. Actual results may differ due to risks including competitive dynamics, pricing pressures, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688513_20260717_CMQV.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688513_20260717_CMQV.\"><\/object><a id=\"wp-block-file--media-c02292f1-105a-4a25-bbb2-f7625660b417\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688513_20260717_CMQV.pdf\">688513_20260717_CMQV<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688513_20260717_CMQV.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c02292f1-105a-4a25-bbb2-f7625660b417\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[557,42,15,1008],"class_list":["post-70277","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-easton-pharmaceutical","tag-first-mover-generic","tag-product-approvals","tag-sha-688513"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Easton Pharmaceutical Secures NMPA Approval for China&#039;s First Generic Remimazolam Besylate, Challenging Humanwell&#039;s Ruima Monopoly in Procedural Sedation and General Anesthesia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has received approval from China&#039;s National Medical Products Administration (NMPA) for two key indications: (1) sedation and anesthesia in non-intubated surgical\/procedural settings; and (2) induction and maintenance of general anesthesia. This marks China&#039;s first generic approval of remimazolam besylate, deemed therapeutically equivalent to the original under Generic Quality Consistency Evaluation (GQCE) requirements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70277\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Easton Pharmaceutical Secures NMPA Approval for China&#039;s First Generic Remimazolam Besylate, Challenging Humanwell&#039;s Ruima Monopoly in Procedural Sedation and General Anesthesia\" \/>\n<meta property=\"og:description\" content=\"Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has received approval from China&#039;s National Medical Products Administration (NMPA) for two key indications: (1) sedation and anesthesia in non-intubated surgical\/procedural settings; and (2) induction and maintenance of general anesthesia. This marks China&#039;s first generic approval of remimazolam besylate, deemed therapeutically equivalent to the original under Generic Quality Consistency Evaluation (GQCE) requirements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70277\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T06:13:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70277#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70277\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Easton Pharmaceutical Secures NMPA Approval for China&#8217;s First Generic Remimazolam Besylate, Challenging Humanwell&#8217;s Ruima Monopoly in Procedural Sedation and General Anesthesia\",\"datePublished\":\"2026-07-20T06:13:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70277\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Easton Pharmaceutical\",\"First-mover generic\",\"Product approvals\",\"SHA: 688513\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70277#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70277\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70277\",\"name\":\"Easton Pharmaceutical Secures NMPA Approval for China's First Generic Remimazolam Besylate, Challenging Humanwell's Ruima Monopoly in Procedural Sedation and General Anesthesia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T06:13:14+00:00\",\"description\":\"Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has received approval from China's National Medical Products Administration (NMPA) for two key indications: (1) sedation and anesthesia in non-intubated surgical\\\/procedural settings; and (2) induction and maintenance of general anesthesia. This marks China's first generic approval of remimazolam besylate, deemed therapeutically equivalent to the original under Generic Quality Consistency Evaluation (GQCE) requirements.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70277#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70277\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70277#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Easton Pharmaceutical Secures NMPA Approval for China&#8217;s First Generic Remimazolam Besylate, Challenging Humanwell&#8217;s Ruima Monopoly in Procedural Sedation and General Anesthesia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Easton Pharmaceutical Secures NMPA Approval for China's First Generic Remimazolam Besylate, Challenging Humanwell's Ruima Monopoly in Procedural Sedation and General Anesthesia - Insight, China&#039;s Pharmaceutical Industry","description":"Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has received approval from China's National Medical Products Administration (NMPA) for two key indications: (1) sedation and anesthesia in non-intubated surgical\/procedural settings; and (2) induction and maintenance of general anesthesia. This marks China's first generic approval of remimazolam besylate, deemed therapeutically equivalent to the original under Generic Quality Consistency Evaluation (GQCE) requirements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70277","og_locale":"en_US","og_type":"article","og_title":"Easton Pharmaceutical Secures NMPA Approval for China's First Generic Remimazolam Besylate, Challenging Humanwell's Ruima Monopoly in Procedural Sedation and General Anesthesia","og_description":"Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has received approval from China's National Medical Products Administration (NMPA) for two key indications: (1) sedation and anesthesia in non-intubated surgical\/procedural settings; and (2) induction and maintenance of general anesthesia. This marks China's first generic approval of remimazolam besylate, deemed therapeutically equivalent to the original under Generic Quality Consistency Evaluation (GQCE) requirements.","og_url":"https:\/\/flcube.com\/?p=70277","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T06:13:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70277#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70277"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Easton Pharmaceutical Secures NMPA Approval for China&#8217;s First Generic Remimazolam Besylate, Challenging Humanwell&#8217;s Ruima Monopoly in Procedural Sedation and General Anesthesia","datePublished":"2026-07-20T06:13:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70277"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Easton Pharmaceutical","First-mover generic","Product approvals","SHA: 688513"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70277#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70277","url":"https:\/\/flcube.com\/?p=70277","name":"Easton Pharmaceutical Secures NMPA Approval for China's First Generic Remimazolam Besylate, Challenging Humanwell's Ruima Monopoly in Procedural Sedation and General Anesthesia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T06:13:14+00:00","description":"Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has received approval from China's National Medical Products Administration (NMPA) for two key indications: (1) sedation and anesthesia in non-intubated surgical\/procedural settings; and (2) induction and maintenance of general anesthesia. This marks China's first generic approval of remimazolam besylate, deemed therapeutically equivalent to the original under Generic Quality Consistency Evaluation (GQCE) requirements.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70277#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70277"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70277#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Easton Pharmaceutical Secures NMPA Approval for China&#8217;s First Generic Remimazolam Besylate, Challenging Humanwell&#8217;s Ruima Monopoly in Procedural Sedation and General Anesthesia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70277"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70277\/revisions"}],"predecessor-version":[{"id":70279,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70277\/revisions\/70279"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}